A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Philippe Moreau
No relevant relationships to disclose
David Avigan
No relevant relationships to disclose
Kenneth Carl Anderson
No relevant relationships to disclose
Donna Ellen Reece
Honoraria - Amgen; Celgene; Janssen; Onyx; Otsuka
Research Funding - Bristol-Myers Squibb; Celgene; Janssen; Merck; Millennium; Novartis; Otsuka
Expert Testimony - Onyx
Jesus San Miguel
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Merck; Millennium; Novartis; Onyx
MarĂa-Victoria Mateos
No relevant relationships to disclose
Dianna Wu
Employment or Leadership Position - Merck
Stock Ownership - Merck
Kenneth Emancipator
Employment or Leadership Position - Merck
Marisa Dolled-Filhart
Employment or Leadership Position - Merck
Christine Gause
Employment or Leadership Position - Merck
Holly Brown
Employment or Leadership Position - Merck
Karl Heath
Employment or Leadership Position - Merck
Robert Iannone
Employment or Leadership Position - Merck
Shelonitda Rose
Employment or Leadership Position - Merck
Robert Z. Orlowski
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Onyx
Honoraria - Bristol-Myers Squibb (I); Celgene; Merck; Millennium; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Onyx